# Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab

> **NCT04114630** · PHASE3 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Migraine

## Interventions

- **DRUG:** erenumab 70mg/mL

## Key facts

- **NCT ID:** NCT04114630
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-10-30
- **Primary completion:** 2021-12-06
- **Final completion:** 2022-01-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients were enrolled and global prioritization of pipeline and research strategy
- **Last updated:** 2020-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04114630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04114630, "Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT04114630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*